Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768105 · ClinicalTrials.gov registry record · Phase 1
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00768105 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT00768105, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.
Interventions
- DRUG Placebo
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768105
The ClinicalTrials.gov registry entry for NCT00768105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00768105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768105 about?
NCT00768105 is a clinical study titled "To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin". The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.
What is the current status of trial NCT00768105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2008-09. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00768105?
The interventions under investigation include: Placebo (DRUG), AZD1656 (DRUG).
Who is sponsoring clinical trial NCT00768105?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.